Search
Dimethylphthalate
go.drugbank.com/drugs/DB13336ExperimentalCategories: Compounds used in a research, industrial, or household settingCyclo(his-pro)
go.drugbank.com/drugs/DB02414ExperimentalCategories: Compounds used in a research, industrial, or household settingCPZEN-45
go.drugbank.com/drugs/DB18077ExperimentalSynonyms: Uridine, 5'-o-(5-amino-5-deoxy-.beta.-d-ribofuranosyl)-5'-c-((2s)-5-(((4-butylphenyl)amino)carbonyl)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1h-1,4-diazepin-2-yl)-, (5's)-, 5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-N-(4-butylphenyl)-4,7-dimethyl-6-oxocyclohept-1-ene-1-carboxamideCategories: Drugs for Treatment of TuberculosisRadotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
Andrographolide
go.drugbank.com/drugs/DB05767InvestigationalThe herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases. … Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China.
Categories: Analgesics, Non-NarcoticAbt-925 anhydrous free base
go.drugbank.com/drugs/DB33803InvestigationalCategories: Receptors, Dopamine D3, antagonists & inhibitorsTripelennamine
go.drugbank.com/drugs/DB00792ApprovedVet approvedIt is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Sitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnIn 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.